Harry Saperstein, MD
Procedural Dermatology · Beverly Hills, CANPI 1689674715
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.
Across 390 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AbbVie$1K
- Galderma Laboratories, L.p.$747
- Regeneron Healthcare Solutions, Inc.$645
- Merz North America, Inc.$561
- Amgen$556
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 45 | $1,288 |
| AbbVie(2 entities) | 50 | $1,023 |
| Galderma Laboratories, L.p. | 41 | $747 |
| Regeneron Healthcare Solutions, Inc. | 25 | $645 |
| Merz North America, Inc. | 7 | $561 |
| Amgen | 24 | $556 |
| Johnson & Johnson | 19 | $411 |
| E.r. Squibb & Sons, L.L.C. | 25 | $409 |
| Pfizer | 17 | $315 |
| Novartis | 15 | $313 |
| Lilly USA, LLC | 14 | $288 |
| LEO Pharma Inc. | 15 | $274 |
| Incyte Corporation | 10 | $239 |
| EPI Health, LLC | 10 | $223 |
| Sun Pharmaceutical Industries Inc. | 9 | $207 |
| Dermavant Sciences, Inc. | 11 | $199 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $150 |
| Mayne Pharma Commercial LLC | 8 | $140 |
| Arcutis Biotherapeutics, Inc. | 8 | $139 |
| Glenmark Therapeutics Inc. | 2 | $132 |
| UCB, Inc. | 5 | $110 |
| VYNE Pharmaceuticals Inc. | 3 | $52 |
| Bristol Myers Squibb | 2 | $49 |
| Journey Medical Corporation | 3 | $44 |
| Krystal Biotech Inc | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Sandoz | 1 | $17 |
| Almirall LLC | 1 | $16 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $15 |
| Encore Dermatology Inc. | 1 | $15 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| Mission Pharmacal Company | 1 | $15 |
| Prugen, Inc. Pharmaceuticals | 1 | $15 |
| Organon | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEMLUVIO$119
How this compares
$8,754 in reported general payments places this provider in the 70th percentile of 108 procedural dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 61 | $292,957 |
| Ketoconazole | 741 | $13,549 |
| Hydrocortisone | 350 | $12,596 |
| JubliaEfinaconazole | 11 | $12,052 |
| CiclopiroxCiclopirox Olamine | 402 | $11,577 |
| Calcipotriene | 26 | $7,614 |
| ValacyclovirValacyclovir Hcl | 194 | $6,788 |
| Clobetasol Propionate | 72 | $6,677 |
| Mupirocin | 1,023 | $6,599 |
| Triamcinolone Acetonide | 452 | $6,508 |
| Tacrolimus | 30 | $5,437 |
| Pimecrolimus | 22 | $4,922 |
| Metronidazole | 67 | $3,905 |
| Clindamycin Phosphate | 110 | $3,857 |
| Fluocinonide | 78 | $3,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $556 | $292,95761 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $150 | $12,05211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 108 procedural dermatology providers in California.
Other procedural dermatology in Beverly Hills
- Robin SchaffranBeverly Hills$11K
- Suzanne BerkmanBeverly Hills$10K
- Annette GottliebBeverly Hills$2K
- Sam Khalifianla Mesa$3.5M
- Sabrina FabiSan Diego$3.1M
- Natasha MesinkovskaMission Viejo$499K
- Jeanette BlackLos Angeles$492K
- Mitchel GoldmanSan Diego$425K
- Rebecca FitzgeraldLos Angeles$230K
- Suzanne KilmerSacramento$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.